About the IVR
IVR Development
IVR development was led by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, with financial support from the Wellcome Trust. A steering group and a global taskforce of subject matter experts provided a wide range of knowledge and experience in influenza vaccines R&D.
Steering Group
Joseph Bresee, MD, Task Force for Global Health, USA
Christopher Chadwick, PhD, MSPH,1 World Health Organization, Switzerland
Martin Friede, PhD, World Health Organization, Switzerland
Bruce Gellin, MD, MPH,2 The Rockefeller Foundation, USA
Josie Golding, PhD, Wellcome Trust, UK
Peter Hart, PhD, Wellcome Trust, UK
Rosalind Hollingsworth, PhD,3 Bill & Melinda Gates Foundation, USA
Stacey Knobler, MSc,1 Sabin Vaccine Institute, USA
Ann Moen, MPA,4 US Centers for Disease Control & Prevention, USA
Sonja Olsen, PhD,5 US Centers for Disease Control & Prevention, USA
Michael Osterholm, PhD, MPH, University of Minnesota, USA
Diane Post, PhD,6 National Institutes of Health, USA
Divya Shah, PhD,7 Wellcome Trust, UK
CIDRAP Core Project Staff
Meredith Arpey, MPH, Research Assistant
Lauren Bigalke, MPH, Research Associate
Anje Mehr, MPH, Research Specialist
Kristine Moore, MD, MPH, Medical Director and IVR Project Director
Julie Ostrowsky, MSc, Research Associate
Angela Ulrich, PhD, MPH, Assistant Professor and IVR Research Scientist
Jim Wappes, Editorial Director
Taskforce Members
William Ampofo, PhD, University of Ghana, Ghana
Ed Belongia, MD,1 Marshfield Clinic Research Institute, USA
David Brown, MBBS,1 Oswaldo Cruz Foundation (FIOCRUZ), Brazil
Wendy Barclay, PhD,8 Imperial College London, UK
Marco Cavaleri, PhD, European Medicines Agency, The Netherlands
Cheryl Cohen, PhD, University of the Witwatersrand, South Africa
Benjamin Cowling, PhD, University of Hong Kong, Hong Kong SAR, China
Rebecca Cox, PhD, University of Bergen, Norway
Amanda Glassman, MSc,1 Center for Global Development, USA
Swati Gupta, PhD, MPH,1 International AIDS Vaccine Institute, USA
Ian Gust, AO, MD, University of Melbourne, Australia
Scott Hensley, PhD,1 University of Pennsylvania, USA
Bruce Innis, MD, PATH Center for Vaccine Innovation & Access, USA
Irina Isakova-Sivak, PhD,1 Institute of Experimental Medicine, Russia
Kari Johansen, MD, PhD,1 European Centre for Disease Prevention and Control (retired), Sweden
Gagandeep (Cherry) Kang, MBBS, MD, PhD, Christian Medical College, India
Eric Karikari-Boateng, MPharm,1 Food and Drugs Authority, Ghana
Jacqueline Katz, PhD,8 US Centers for Disease Control & Prevention (retired), USA
Yoshihiro Kawaoka, DVM, PhD,8 University of Wisconsin–Madison, USA
Florian Krammer, PhD, Icahn School of Medicine at Mount Sinai, USA
John CW Lim, MBBS, MS,1 Duke-National University of Singapore Medical School, Singapore
John McCauley, PhD,1 Frances Crick Institute, UK
Janet McElhaney, MD,1,9 Health Sciences North Research Institute, Canada
Richard Pebody, MBChB, PhD,1 World Health Organization, Switzerland
Punnee Pitisuttithum, MD, Mahidol University, Thailand
Rino Rappuoli, PhD,1 National Institute for Pandemic Preparedness, Italy
Tiago Rocca,1 Instituto Butantan, Brazil
Meta Roestenberg, MD, PhD,1,10 Leiden University, The Netherlands
Larisa Rudenko, MD, PhD, DSc,8 Institute of Experimental Medicine, Russia
Stacey Schultz-Cherry, PhD,1 St Jude Children’s Research Hospital, USA
Ethan Settembre, PhD,1 Seqirus, USA
Yue-Long Shu, PhD,1 China Center for Disease Control and Prevention, China
Marilda Siqueira, PhD,8 Oswaldo Cruz Foundation (FIOCRUZ), Brazil
James Southern, PhD,1 Adviser to South African Health Products Regulatory Authority, South Africa
Kanta Subbarao, MBBS,1 Doherty Institute, Australia
John S. Tam, PhD,1 Hong Kong Polytechnic University, Hong Kong SAR, China
Rajeev Venkayya, MD,1 Aerium Therapeutics, USA
Jerry Weir, PhD, Food and Drug Administration, USA
~~~
1 New Taskforce member for the IVR implementation phase
2 Previously with the Sabin Vaccine Institute (USA)
3 Since Mar 2021; previous BMGF representatives were Padmini Srikantiah, MD, MPH; Francesco Berlando Scorza, PhD; and Janet White, MBA
4 Steering Group member through Dec 2022
5 Steering Group member as of Jan 2023
6Taskforce member for the development phase; joined the Steering Group for the implementation phase
7 Steering Group member for Jan 2021 through Aug 2021
8 Member of the IVR Taskforce for the development phase; retired
9 In memoriam, Dr. Janet E. McElhaney, 1954-2021; Scientific Director, Health Sciences North Research Institute, Sudbury, Ontario, Canada
10 Member of the IVR Taskforce for the implementation phase; retired